The goal of this study is to collect pilot data using the neuromelanin sensitive MRI sequence in patients with schizophrenia of psychoses, patients with Parkinson's disease and healthy controls. These pilot data will be used for grant…
ID
Source
Brief title
Condition
- Movement disorders (incl parkinsonism)
- Schizophrenia and other psychotic disorders
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
The difference between patients and healthy controls in neuromelanin
concentration (or indirect quantitative measure or this) in the substantia
nigra and locus coeruleus.
Secondary outcome
Correlations between neuromelanin concentrations (or indirect quantitative
measure or this) in the substantia nigra or locus coeruleus and therapy
resistance or side effects of therapy (such as extrapyramidal symptoms).
Background summary
Recently a new MRI sequence was developed, which enables us to visualized and
quantify neuromelanin in the substantia nigra and locus coeruleus. The
substantia nigra and locus coeruleus are core regions of, respectively, the
dopaminergic and noradrenergic system. Dopamine synthesis and release are
increased in schizophrenia, whereas in Parkinson's disease there is
degeneration of dopaminergic neurons in the substantia nigra and noradrenergic
neurons in the locus coeruleus. The first results of the new MRI sequence
indeed suggest that neuromelanin concentration in the substantia nigra is
increase in schizophrenia and decreased in Parkinson's disease.
The new MRI sequence provides a new opportunity to study the dopamine system
and to potentially apply it for clinical use to support the clinical diagnosis
of Parkinson's disease or to predict therapy resistance or extrapyramidal
side-effects by antipsychotics in schizophrenia, in a non-invasie way and
without radiation exposure.
Study objective
The goal of this study is to collect pilot data using the neuromelanin
sensitive MRI sequence in patients with schizophrenia of psychoses, patients
with Parkinson's disease and healthy controls. These pilot data will be used
for grant applications for research projects assessing the clinical
applicability of this MRI sequence in schizophrenia and Parkinson's disease.
Study design
Observational
The pilot data will be used primarily to study differences between patients and
healthy controls. Secondarily, we will assess whether the data shows a
correlation with clinical parameters, such as therapy resistance or
extrapyramidal symptoms. The data will also be used for statistical power
analyses for future studies.
Study burden and risks
Because the participants will get an MRI scan for scientific research or
diagnostics, the increase of scantime by 10-15 minutes has no additional risks
for the participants.
It means for the participants that they will lie in the MRI scanner for 10-15
more minutes. Before start of the additional MRI sequence, they can tell
whether they are still comfortable and whether they still agree to lie 10-15
more minutes in the MRI scanner.
Meibergdreef 9
Amsterdam 1105 AZ
NL
Meibergdreef 9
Amsterdam 1105 AZ
NL
Listed location countries
Age
Inclusion criteria
Patients with schizofrenia/psycosis:
* clinical diagnosis schizophrenia or schizophreniphorm disorder or psychotic episode;Patients with Parkinson's disease
* clinical diagnosis Parkinson's disease, strong indication of Parkinson's disease or Parkinsonian symptoms;Healthy controls:
* age- and gender matched with patients at group level;All participants:
* Capacity to understand the study and to sign *informed consent*.
Exclusion criteria
Healthy controls:
* Severe neurologic and psychiatric disorders
* Use of psychotropic drugs or drugs of abuse that may influence the dopamine system;All participants:
- contra-indications for MRI (including pacemaker, ferromagnetic implants, possibility of iron splinters in the orbita, claustrophobia )
- pregnancy
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL58706.018.16 |